Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 4/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.31 |
| ▸ | NAMPT | P43490 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | METAP1 | P53582 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25993223 | 0.91 | THRB (0.33) | THRBGAAPOLBNAMPTLMNA | |
| SCHEMBL25993269 | 0.89 | METAP1 (0.31) | METAP1 | |
| SCHEMBL25993234 | 0.88 | THRB (0.44) | THRBGAAPOLBLMNA | |
| SCHEMBL27120066 | 0.81 | SIGMAR1 (0.30) | — | |
| SCHEMBL23240153 | 0.80 | THRB (0.32) | THRBMETAP1 | |
| SCHEMBL26020707 | 0.80 | THRB (0.43) | THRBGAAPOLBLMNA | |
| SCHEMBL27124438 | 0.80 | KDM4E (0.38) | THRBGAAPOLBNAMPTLMNA | |
| SCHEMBL24790237 | 0.80 | HRH3 (0.37) | NAMPT | |
| SCHEMBL19116969 | 0.79 | THRB (0.31) | THRB | |
| SCHEMBL27118055 | 0.79 | METAP1 (0.35) | METAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4306111-A2 | 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | Novartis AG (CH) | 2024-01-17 | — | — | EP | disclosed |
| EP-3820573-B1 | 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF IKAROS FAMILY ZINC FINGER 2 (IKZF2)-DEPENDENT DISEASES | NOVARTIS AG (CH) | 2023-08-09 | — | — | EP | disclosed |